AF
MRNA icon

Amalgamated Financial’s Moderna MRNA Stock Holding History

Amalgamated Financial’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$15.8M Buy
+91,984
New +$15.5M 0.13% 129

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Amalgamated Financial's MRNA Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Moderna (MRNA) in Q1 2022: 91,984 shares worth $15.8M. The stake represents 0.13% of the portfolio and ranks #129 among its holdings.

1,007 funds tracked by Wall St. Rank hold MRNA as of Q1 2022.

  • Amalgamated Financial held 91,984 shares of Moderna worth $15.8M as of Q1 2022.
  • Moderna was a new Amalgamated Financial position in Q1 2022.
  • Moderna made up 0.13% of Amalgamated Financial's portfolio in Q1 2022, its #129 holding.
  • 1,007 funds tracked by Wall St. Rank held Moderna as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.